Jing Xu

Dr. Jing Xu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2025 in World Journal of Gastroenterology
Verified
Journal Article
Open access
GQGao-Xiu Qi
Gao-Xiu Qi
RZRui-Xia Zhao
Rui-Xia Zhao
CGChen Gao
Chen Gao
ZMZeng-Yan Ma
Zeng-Yan Ma
SWShang Wang
Shang Wang
JXJing Xu
Jing Xu
Colorectal cancer (CRC) ranks among the top causes of cancer-related fatalities globally. Recent progress in genomics, proteomics, and bioinformatics has greatly improved our comprehension of the molecular underpinnings of CRC, paving the way for targeted therapies and immunotherapies. Nonetheless, obstacles such as tumor heterogeneity and drug resistance persist, hindering advancements in treatment efficacy. In this context, the integration of artificial intelligence (AI) and organoid technology presents promising new avenues. AI can analyze genetic and clinical data to forecast disease risk, prognosis, and treatment responses, thereby expediting drug development and tailoring treatment plans. Organoids replicate the genetic traits and biological behaviors of tumors, acting as platforms for drug testing and the formulation of personalized treatment approaches. Despite notable strides in CRC research and treatment - from genetic insights to therapeutic innovations - numerous challenges endure, including the intricate tumor microenvironment, tumor heterogeneity, adverse effects of immunotherapies, issues related to AI data quality and privacy, and the need for standardization in organoid culture. Future initiatives should concentrate on clarifying the pathogenesis of CRC, refining AI algorithms and organoid models, and creating more effective therapeutic strategies to alleviate the global impact of CRC.

1 February 2016 in Pathology - Research and Practice
Verified
Journal Article
Closed access
JXJing Xu
Jing Xu
XTXiaoyan Tang
Xiaoyan Tang
YIYuko Iida
Yuko Iida
FFFumi Fuchinoue
Fumi Fuchinoue
TKTomomi Kusumi
Tomomi Kusumi
SMShinobu Masuda
Shinobu Masuda

8 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
BMBenxu Ma
Benxu Ma
WMWenjun Miao
Wenjun Miao
JXJieqiong Xiao
Jieqiong Xiao
XCXinyi Chen
Xinyi Chen
JXJing Xu
Jing Xu
YLYinan Li
Yinan Li
Forkhead box protein 3 (FOXP3) is an important transcription factor for regulatory T cells (Tregs) and plays an important role in their immunosuppressive function. In recent years, studies have found that FOXP3 is expressed in many kinds of tumors and plays different roles in tumors’ biological behaviors, including tumor proliferation, metastasis, drug resistance, and prognosis. However, the effects of FOXP3 on tumor metastasis and its interaction with traditional Chinese medicine (TCM) remain unclear. Therefore, in this review, we focus on the effects of FOXP3 on tumor metastasis and its relationship with TCM, which can provide evidence for further research and therapy in clinical settings.

1 January 2020
Verified
Closed access
HMHongfei Ma
Hongfei Ma
YWYanli Wang
Yanli Wang
PCPeng Chen
Peng Chen
ZZZhixue Zhang
Zhixue Zhang
JXJing Xu
Jing Xu